PMID- 12232452
OWN - NLM
STAT- MEDLINE
DCOM- 20021212
LR  - 20171101
IS  - 0025-7931 (Print)
IS  - 0025-7931 (Linking)
VI  - 69
IP  - 5
DP  - 2002
TI  - Low-molecular-weight heparin versus unfractionated heparin in the treatment of 
      patients with acute pulmonary thromboembolism.
PG  - 440-4
AB  - BACKGROUND: Low-molecular-weight heparin (LMWH) appears to be as effective as 
      unfractionated heparin (UFH) for both treatment and prophylaxis of deep vein 
      thrombosis (DVT), but limited data are available for its use in acute pulmonary 
      thromboembolism (PTE). OBJECTIVE: To determine whether enoxaparin, a LMWH, was 
      clinically as efficient and safe as UFH in patients with a diagnosis of acute 
      PTE. MATERIAL AND METHODS: After exclusion of those with massive forms, 59 
      patients with acute PTE were randomly assigned to either subcutaneous enoxaparin 
      given twice daily (1 mg/kg/dose) or adjusted dose intravenous UFH. Oral 
      anticoagulant treatment was begun on the second day and was given for at least 6 
      months. We compared the treatment regimens at day 8 and day 90 with respect to a 
      combined end point of major bleeding, recurrent venous thromboembolism (VTE), and 
      death. RESULTS: In the first 8 days of treatment, 1 of 30 patients assigned to 
      receive UFH (3.3%) reached one of the end points (recurrence), as compared with 
      none of 29 patients assigned to enoxaparin. Statistically this difference was not 
      significant (p = 0.508). By day 90, 3 patients assigned to UFH (10%) had 
      symptomatic recurrent VTE, as compared with 1 patient assigned to enoxaparin 
      (3.4%). There was neither major bleeding nor death in the study groups. There was 
      an absolute difference of 6.4 percentage points between the two treatment groups, 
      but the difference was statistically not significant (p = 0.318). CONCLUSION: 
      Initial subcutaneous treatment with enoxaparin appeared to be as effective and 
      safe as UFH in acute PTE.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Findik, Serhat
AU  - Findik S
AD  - Department of Pulmonary Medicine, 19 Mayis University, Samsun, Turkey. 
      serhatf@omu.edu.tr
FAU - Erkan, M Levent
AU  - Erkan ML
FAU - Selcuk, M Bekir
AU  - Selcuk MB
FAU - Albayrak, Selahattin
AU  - Albayrak S
FAU - Atici, Atilla G
AU  - Atici AG
FAU - Doru, Fatma
AU  - Doru F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Switzerland
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Acute Disease
MH  - Administration, Oral
MH  - Anticoagulants/*therapeutic use
MH  - Enoxaparin/*therapeutic use
MH  - Female
MH  - Heparin/*therapeutic use
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Pulmonary Embolism/diagnostic imaging/*drug therapy
MH  - Radiography
MH  - Recurrence
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2002/09/17 10:00
MHDA- 2002/12/13 04:00
CRDT- 2002/09/17 10:00
PHST- 2002/09/17 10:00 [pubmed]
PHST- 2002/12/13 04:00 [medline]
PHST- 2002/09/17 10:00 [entrez]
AID - 64023 [pii]
AID - 10.1159/000064023 [doi]
PST - ppublish
SO  - Respiration. 2002;69(5):440-4. doi: 10.1159/000064023.